Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""natalizumab"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 41-60 z 7086
Tytuł:
Vaccine-associated measles in a patient treated with natalizumab: a case report.
Autorzy:
Miauton A; Tropical, travel and vaccination clinic, Unisanté, Center for primary care and public health, Bugnon 44, 1011, Lausanne, Switzerland. .
Tan R; Tropical, travel and vaccination clinic, Unisanté, Center for primary care and public health, Bugnon 44, 1011, Lausanne, Switzerland.
Pantazou V; Department of Neurology, Lausanne University Hospital, Bugnon 46, 1011, Lausanne, Switzerland.
Du Pasquier R; Department of Neurology, Lausanne University Hospital, Bugnon 46, 1011, Lausanne, Switzerland.
Genton B; Tropical, travel and vaccination clinic, Unisanté, Center for primary care and public health, Bugnon 44, 1011, Lausanne, Switzerland.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2020 Oct 14; Vol. 20 (1), pp. 753. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Measles/*etiology
Measles Vaccine/*adverse effects
Measles-Mumps-Rubella Vaccine/*therapeutic use
Natalizumab/*therapeutic use
Adult ; Exanthema/chemically induced ; Female ; Fever/etiology ; Humans ; Immunologic Factors/therapeutic use ; Immunosuppression Therapy/adverse effects ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Measles/diagnosis ; Measles Vaccine/therapeutic use ; Measles-Mumps-Rubella Vaccine/adverse effects ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Natalizumab/immunology ; Vaccines, Attenuated/adverse effects ; Vaccines, Attenuated/immunology ; Vaccines, Attenuated/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Autorzy:
Vollmer BL; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver, Colorado.
Nair K; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver, Colorado.; Skagg's School of Pharmacy and Pharmaceutical Sciences at Anschutz Medical Campus, University of Colorado, Denver, Colorado.
Sillau S; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver, Colorado.
Corboy JR; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver, Colorado.
Vollmer T; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver, Colorado.
Alvarez E; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver, Colorado.
Pokaż więcej
Źródło:
Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2020 Sep; Vol. 7 (9), pp. 1466-1476. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji:
Comparative Study; Journal Article; Observational Study
MeSH Terms:
Outcome Assessment, Health Care*
Dimethyl Fumarate/*pharmacology
Fingolimod Hydrochloride/*pharmacology
Immunologic Factors/*pharmacology
Multiple Sclerosis, Chronic Progressive/*drug therapy
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Natalizumab/*pharmacology
Rituximab/*pharmacology
Adult ; Dimethyl Fumarate/administration & dosage ; Dimethyl Fumarate/adverse effects ; Female ; Fingolimod Hydrochloride/administration & dosage ; Fingolimod Hydrochloride/adverse effects ; Follow-Up Studies ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis, Chronic Progressive/pathology ; Multiple Sclerosis, Chronic Progressive/physiopathology ; Multiple Sclerosis, Relapsing-Remitting/pathology ; Multiple Sclerosis, Relapsing-Remitting/physiopathology ; Natalizumab/administration & dosage ; Natalizumab/adverse effects ; Recurrence ; Retrospective Studies ; Rituximab/administration & dosage ; Rituximab/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.
Autorzy:
Baroncini D; Multiple Sclerosis Center, Gallarate Hospital, ASST Valle Olona, Gallarate, VA, Italy. .
Ghezzi A; Multiple Sclerosis Center, Gallarate Hospital, ASST Valle Olona, Gallarate, VA, Italy.; Dipartimento Di Scienze Della Salute, Università del Piemonte Orientale, Novara, Italy.
Guaschino C; Multiple Sclerosis Center, Gallarate Hospital, ASST Valle Olona, Gallarate, VA, Italy.
Moiola L; Multiple Sclerosis Center-Neurology Department, San Raffaele Hospital IRCCS, Milano, Italy.
Filippi M; Department of Neurology, Neurorehabilitation and Neurophysiology, MS Center, and Neuroimaging Research Unit, Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milan, Italy.
Ianniello A; Department of Human Neurosciences, S.Andrea Multiple Sclerosis Center, Sapienza University, Rome, Italy.
Pozzilli C; Department of Human Neurosciences, S.Andrea Multiple Sclerosis Center, Sapienza University, Rome, Italy.
Lanzillo R; Department of Neurosciences and Reproductive and Odontostomatological Sciences, University 'Federico II', Naples, Italy.
Brescia-Morra V; Department of Neurosciences and Reproductive and Odontostomatological Sciences, University 'Federico II', Naples, Italy.
Margoni M; Multiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, Italy.; Padova Neuroscience Centre (PNC), University of Padua, Padua, Italy.
Gallo P; Multiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, Italy.; Padova Neuroscience Centre (PNC), University of Padua, Padua, Italy.
Callari G; Foundation Institute 'G. Giglio', MS Center, Cefalù-Palermo, Italy.
Grimaldi L; Foundation Institute 'G. Giglio', MS Center, Cefalù-Palermo, Italy.
Lus G; Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Calabrese M; Department of Neuroscience, Biomedicine and Movement, The Multiple Sclerosis Center of the University Hospital of Verona, Verona, Italy.
Simone M; Child Neuropsychiatry Unit, Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy.
Marfia GA; MS Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Rasia S; Multiple Sclerosis Center, ASST - Spedali Civili of Brescia, Montichiari, Brescia, Italy.
Cargnelutti D; Neurology Unit, Udine University Hospital, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.
Comi G; Multiple Sclerosis Center, Gallarate Hospital, ASST Valle Olona, Gallarate, VA, Italy.; Casa Di Cura del Policlinico, Milan, Italy.
Zaffaroni M; Multiple Sclerosis Center, Gallarate Hospital, ASST Valle Olona, Gallarate, VA, Italy.
Pokaż więcej
Corporate Authors:
MS Study Group of the Italian Neurological Society
Źródło:
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2022 Nov; Vol. 43 (11), pp. 6415-6423. Date of Electronic Publication: 2022 Jul 04.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Multiple Sclerosis*/drug therapy
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Adult ; Female ; Humans ; Child ; Natalizumab/adverse effects ; Follow-Up Studies ; Retrospective Studies ; Recurrence ; Immunologic Factors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study.
Autorzy:
Castellazzi, Massimiliano (AUTHOR)
Ferri, Caterina (AUTHOR)
Piola, Alice (AUTHOR)
Permunian, Samantha (AUTHOR)
Buscemi, Gaia (AUTHOR)
Laudisi, Michele (AUTHOR)
Baldi, Eleonora (AUTHOR)
Pugliatti, Maura (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Jan2023, Vol. 24 Issue 2, p1500. 11p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Qualitative and Quantitative Molecular Analysis of Epstein-Barr Virus in Iraqi Patients with Relapsing-Remitting Multiple Sclerosis.
Autorzy:
Atiyah, Noor S.
Fadhil, Hula Y.
Ad'hiah, Ali H.
Pokaż więcej
Alternatywny tytuł:
تحليل جزيئي نوعي و كمي لفيروس ابشتاين بار بين المرضى العراقيين المصابين بالتصلب المتعدد االنتكاسي المتحول.
Źródło:
Iraqi Journal of Science. 2023, Vol. 64 Issue 1, p127-137. 11p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report.
Autorzy:
De Masi, Roberto (AUTHOR)
Orlando, Stefania (AUTHOR)
Armenise, Silvia (AUTHOR)
Spagnolo, Pantaleo (AUTHOR)
Capra, Ruggero (AUTHOR)
Costa, Maria Carmela (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Nov2022, Vol. 23 Issue 21, p13642. 7p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
Autorzy:
Dominguez-Mozo MI; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain.
Perez-Perez S; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain.
Villar LM; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Oliver-Martos B; UGC Neurociencias. Hospital Regional Universitario de Málaga/Instituto de Biomedicina de Málaga (IBIMA), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Villarrubia N; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Matesanz F; Departmento de Biología Celular E Inmunología, Instituto de Parasitología Y Biomedicina López Neyra (IPBLN)/Consejo Superior de Investigaciones Científicas (CSIC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Costa-Frossard L; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Pinto-Medel MJ; UGC Neurociencias. Hospital Regional Universitario de Málaga/Instituto de Biomedicina de Málaga (IBIMA), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
García-Sánchez MI; UGC Neurología (Biobanco Hospitalario), Hospital Universitario Virgen Macarena, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Ortega-Madueño I; Servicio de Análisis Clínicos, Hospital Clínico San Carlos, Madrid, Spain.
Lopez-Lozano L; Servicio de Análisis Clínicos, Hospital Clínico San Carlos, Madrid, Spain.
Garcia-Martinez A; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain.
Izquierdo G; UGC Neurología, Hospital Universitario Virgen Macarena, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Fernández Ó; UGC Neurociencias. Hospital Regional Universitario de Málaga/Instituto de Biomedicina de Málaga (IBIMA), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Álvarez-Cermeño JC; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Arroyo R; Departamento de Neurología, Hospital Universitario Quironsalud Madrid, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Alvarez-Lafuente R; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Aug 28; Vol. 10 (1), pp. 14244. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers, Pharmacological/*analysis
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adult ; Antibody Formation ; Biomarkers, Pharmacological/blood ; Capsid Proteins/analysis ; Capsid Proteins/immunology ; Disease Progression ; Epstein-Barr Virus Infections/immunology ; Epstein-Barr Virus Nuclear Antigens/analysis ; Female ; HLA Antigens/analysis ; Herpesvirus 4, Human/immunology ; Herpesvirus 6, Human/immunology ; Humans ; Immunoglobulin G/analysis ; Longitudinal Studies ; Male ; Middle Aged ; Multiple Sclerosis/immunology ; Natalizumab/metabolism ; Prognosis ; Recurrence ; Retrospective Studies ; Spain
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
Autorzy:
Julian GS; IQVIA Brasil, São Paulo-SP, Brazil.
Rosim RP; Biogen Brasil, São Paulo-SP, Brazil.
Carneseca EC; Proestat Consultoria Estatística, Ribeirão Preto-SP, Brazil.
Rigolon J; Biogen Brasil, São Paulo-SP, Brazil.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 Mar 02; Vol. 15 (3), pp. e0229768. Date of Electronic Publication: 2020 Mar 02 (Print Publication: 2020).
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fingolimod Hydrochloride/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Natalizumab/*therapeutic use
Administrative Claims, Healthcare/statistics & numerical data ; Adult ; Aged ; Brazil ; Female ; Fingolimod Hydrochloride/administration & dosage ; Fingolimod Hydrochloride/adverse effects ; Hospitalization/statistics & numerical data ; Hospitals, Public/statistics & numerical data ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Natalizumab/administration & dosage ; Natalizumab/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Autorzy:
Auer M; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Sellner J; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Oppermann K; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Bsteh G; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Di Pauli F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Berger T; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Deisenhammer F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło:
Brain and behavior [Brain Behav] 2019 Jul; Vol. 9 (7), pp. e01332. Date of Electronic Publication: 2019 Jun 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral/*immunology
Immunologic Factors/*therapeutic use
JC Virus/*immunology
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adult ; Antibodies, Viral/blood ; Cohort Studies ; Denmark ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Humans ; Immunologic Factors/blood ; Longitudinal Studies ; Male ; Multiple Sclerosis/blood ; Multiple Sclerosis/immunology ; Natalizumab/blood ; Prospective Studies ; Seroconversion
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Autorzy:
Perumal J; Weill Cornell Multiple Sclerosis Center, New York, NY, USA.
Fox RJ; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Balabanov R; Northwestern University, Chicago, IL, USA.
Balcer LJ; New York University School of Medicine, New York, NY, USA.
Galetta S; New York University School of Medicine, New York, NY, USA.
Makh S; Biogen, 225 Binney St, Cambridge, MA, 02142, USA.
Santra S; Biogen, 225 Binney St, Cambridge, MA, 02142, USA.
Hotermans C; Biogen, 225 Binney St, Cambridge, MA, 02142, USA.
Lee L; Biogen, 225 Binney St, Cambridge, MA, 02142, USA. .
Pokaż więcej
Źródło:
BMC neurology [BMC Neurol] 2019 Jun 08; Vol. 19 (1), pp. 116. Date of Electronic Publication: 2019 Jun 08.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Outcome Assessment, Health Care*
Immunologic Factors/*pharmacology
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Natalizumab/*pharmacology
Adult ; Female ; Humans ; Immunologic Factors/administration & dosage ; Male ; Middle Aged ; Natalizumab/administration & dosage ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
Autorzy:
Evdoshenko E; SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia.
Stepanova A; SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia.
Shumilina M; SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia.
Davydovskaya M; State Budgetary Institution of Moscow City 'Clinical Trials and Healthcare Technology Assessment Scientific-Research Centre of Moscow Department of Healthcare', Moscow, Russian Federation.; Pirogov Russian National Research Medical University, Moscow, Russia.
Khachanova N; Pirogov Russian National Research Medical University, Moscow, Russia.
Neofidov N; SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia.
Kalinin I; SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia.
Popova E; City Clinical Hospital # 24, Moscow, Russia.
Dubchenko E; City Clinical Hospital # 81, Moscow, Russia.
Pozhidaeva N; City Clinical Hospital # 81, Moscow, Russia.
Volkov A; City Clinical Hospital # 71, Moscow, Russia.
Sivertseva S; 'Medical Sanitary Unit «Neftyanik», Tyumen Multiple Sclerosis Center, Tyumen, Russia.
Prilenskaya A; 'Medical Sanitary Unit «Neftyanik», Tyumen Multiple Sclerosis Center, Tyumen, Russia.
Malkova N; State Novosibirsk Regional Clinical Hospital, Center of MS and other AID of Nervous System, Novosibirsk, Russia.; State Novosibirsk Medical University, Novosibirsk, Russia.
Korobko D; State Novosibirsk Regional Clinical Hospital, Center of MS and other AID of Nervous System, Novosibirsk, Russia.
Vergunova I; State Novosibirsk Regional Clinical Hospital, Center of MS and other AID of Nervous System, Novosibirsk, Russia.
Shchur S; City Clinical Hospital # 15, Moscow, Russia.
Makshakov G; SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 May 28; Vol. 14 (5), pp. e0217303. Date of Electronic Publication: 2019 May 28 (Print Publication: 2019).
Typ publikacji:
Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Immunologic Factors/*therapeutic use
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Natalizumab/*therapeutic use
Adult ; Cross-Sectional Studies ; Female ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Leukoencephalopathy, Progressive Multifocal/etiology ; Leukoencephalopathy, Progressive Multifocal/prevention & control ; Male ; Natalizumab/administration & dosage ; Natalizumab/adverse effects ; Retrospective Studies ; Risk Management ; Russia ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim.
Autorzy:
Sips FLP; InSilicoTrials Technologies, 's-Hertogenbosch, Netherlands.
Pappalardo F; Department of Drug and Health Sciences, University of Catania, Catania, Italy.; Mimesis Srl, Catania, Italy.
Russo G; Department of Drug and Health Sciences, University of Catania, Catania, Italy.; Mimesis Srl, Catania, Italy.
Bursi R; InSilicoTrials Technologies, 's-Hertogenbosch, Netherlands. .
Pokaż więcej
Źródło:
BMC medical informatics and decision making [BMC Med Inform Decis Mak] 2022 Nov 15; Vol. 22 (Suppl 6), pp. 294. Date of Electronic Publication: 2022 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Multiple Sclerosis*
Humans ; Natalizumab/therapeutic use ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
Autorzy:
Silva GD; Neurology Department, University of São Paulo, São Paulo, Brazil.
Castrillo BB; Neurology Department, University of São Paulo, São Paulo, Brazil.; Neurology Department, University of Espírito Santo, Vitória, Brazil.
Apóstolos-Pereira SL; Neurology Department, University of São Paulo, São Paulo, Brazil.
Callegaro D; Neurology Department, University of São Paulo, São Paulo, Brazil.
Pokaż więcej
Źródło:
Acta neurologica Scandinavica [Acta Neurol Scand] 2022 Nov; Vol. 146 (5), pp. 403-409. Date of Electronic Publication: 2022 Sep 02.
Typ publikacji:
Journal Article; Meta-Analysis; Review
MeSH Terms:
Multiple Sclerosis*/drug therapy
Multiple Sclerosis, Chronic Progressive*/drug therapy
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Azetidines ; Benzyl Compounds ; Fingolimod Hydrochloride/therapeutic use ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Natalizumab/therapeutic use ; Network Meta-Analysis ; Off-Label Use ; Rituximab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients.
Autorzy:
Balasa, Rodica (AUTHOR)
Maier, Smaranda (AUTHOR)
Hutanu, Adina (AUTHOR)
Voidazan, Septimiu (AUTHOR)
Andone, Sebastian (AUTHOR)
Oiaga, Mirela (AUTHOR)
Manu, Doina (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Sep2022, Vol. 23 Issue 18, pN.PAG-N.PAG. 16p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β.
Autorzy:
Muñoz, Úrsula (AUTHOR)
Sebal, Cristina (AUTHOR)
Escudero, Esther (AUTHOR)
Urcelay, Elena (AUTHOR)
Arroyo, Rafael (AUTHOR)
García-Martínez, Maria A. (AUTHOR)
Quintana, Francisco J. (AUTHOR)
Álvarez-Lafuente, Roberto (AUTHOR)
Sádaba, Maria Cruz (AUTHOR)
Pokaż więcej
Źródło:
Scientific Reports. 8/3/2022, Vol. 12 Issue 1, p1-10. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 41-60 z 7086

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies